country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-184705

Copy Link Print Information

HDAC-IN-105

HDAC-IN-105 is a histone deacetylase (HDAC) inhibitor with binding to HDAC2 and HDAC4 isoforms. HDAC-IN-105 suppresses HDAC activity via binding within conserved HDAC catalytic pockets. HDAC-IN-105 induces G2/M phase cell cycle arrest. HDAC-IN-105 triggers mitochondrial dysfunction marked by loss of mitochondrial membrane potential. HDAC-IN-105 exhibits growth inhibition in triple-negative breast cancer cells and low toxicity toward normal cells. HDAC-IN-105 can be used for the research of triple-negative breast cancer.

For research use only. We do not sell to patients.

Formula: C₂₆H₂₈BrN₅O
Molecular Weight:506.44

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

HDAC-IN-105 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

HDAC2

HDAC4

All HDAC Isoforms :

In Vitro

Anti-cancerApoptosisCell Cycle RegulationMitochondrial FunctionOthers

Anti-cancer

HDAC-IN-105 (10-100 μM; 24 h) exhibits potent antiproliferative activity with an IC50 of 27.59 μM in MDA-MB-231 cells, 34.18 μM in MCF-7 cells, 64.21 μM in HUVEC cells, and 105.23 μM in HDF cells^[1].

Anti-cancer

Apoptosis

HDAC-IN-105 (20-30 μM; 24 h) dose-dependently induces apoptosis in MDA-MB-231 triple-negative breast cancer cells after 24 h of incubation, increasing apoptotic cell percentage up to 24.5%^[1].

Anti-cancer

Cell Cycle Regulation

HDAC-IN-105 (20-30 μM; 24 h) at 30 μM induces G2/M phase cell cycle arrest in MDA-MB-231 triple-negative breast cancer cells after 24 h of incubation, increasing the percentage of cells in G2/M phase from 20.6% to 33.2%^[1].

Anti-cancer

Mitochondrial Function

HDAC-IN-105 (20-30 μM; 24 h) dose-dependently induces loss of mitochondrial membrane potential in MDA-MB-231 triple-negative breast cancer cells after 24 h of incubation, affecting up to 54% of cells^[1].

Others

HDAC-IN-105 (Compound 7e) (5-30 μM; 24 h) concentration-dependently reduces total cellular HDAC activity in MDA-MB-231 triple-negative breast cancer cells, with an apparent IC₅₀ of 26.58 μM and a 63% reduction at 30 μM after 24 h of incubation^[1].
HDAC-IN-105 (20-30 μM; 24 h) induces dose-dependent cytotoxic morphological changes in MDA-MB-231 triple-negative breast cancer cells after 24 h of incubation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:

MDA-MB-231 triple-negative breast cancer cells
Concentration:

20 and 30 μM
Incubation Time:

24 h
Result:

Increased the percentage of cells in G2/M phase from 20.6% (control) to 19.5% with a corresponding increase in S phase to 30.9% at 20 μM.
Increased G2/M phase cells to 33.2% with S phase at 37.3% and G1 phase reduced to 29.5% at 30 μM.

Apoptosis Analysis^[1]

Cell Line:

MDA-MB-231 triple-negative breast cancer cells
Concentration:

20 and 30 μM
Incubation Time:

24 h
Result:

Increased the percentage of apoptotic cells from 6.21% (control) to 13% at 20 μM.
Increased apoptotic cells to 24.5% at 30 μM.

Related Protocols :

Chemical Information

Molecular Weight 506.44
Formula C₂₆H₂₈BrN₅O
SMILES

BrC(C=C1)=CC=C1N2N=NC(COCCN(CC3)CCN3CC4=CC=C(C=CC=C5)C5=C4)=C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Moghtaderi H, et al. A piperazine-triazole hybrid triggers G2/M arrest in triple-negative breast Cancer cells by suppressing HDAC activity and disrupting mitochondrial membrane potential. Bioorganic chemistry. 2026 Jun 18;180:110114. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

HDAC-IN-105

All HDAC Isoforms

Biological Activity

Description

IC50 & Target

In Vitro

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

HDAC-IN-105 Related Classifications

HY-184705 Related Classifications

Bioz

Keywords

Your Recently Viewed Products

IC₅₀ & Target